Cargando…

Impact of night-time symptoms in COPD: a real-world study in five European countries

BACKGROUND: Sleep quality is often poor in patients with chronic obstructive pulmonary disease (COPD). A cross-sectional European survey investigated the prevalence of night-time symptoms in COPD to evaluate the level of disconnect between physician and patient perceptions of the presence of night-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, David, Small, Mark, Milligan, Gary, Higgins, Victoria, Gil, Esther Garcia, Estruch, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849086/
https://www.ncbi.nlm.nih.gov/pubmed/24348032
http://dx.doi.org/10.2147/COPD.S48570
_version_ 1782293875835011072
author Price, David
Small, Mark
Milligan, Gary
Higgins, Victoria
Gil, Esther Garcia
Estruch, Jordi
author_facet Price, David
Small, Mark
Milligan, Gary
Higgins, Victoria
Gil, Esther Garcia
Estruch, Jordi
author_sort Price, David
collection PubMed
description BACKGROUND: Sleep quality is often poor in patients with chronic obstructive pulmonary disease (COPD). A cross-sectional European survey investigated the prevalence of night-time symptoms in COPD to evaluate the level of disconnect between physician and patient perceptions of the presence of night-time symptoms, and to compare the characteristics of patients with and without night-time symptoms. METHODS: A total of 251 primary care physicians and 251 respiratory specialists completed record forms on 2,807 patients with COPD. The forms captured information on patient demographics, lung function, COPD severity, and symptoms. Patients completed questionnaires on the time of day when their COPD symptoms bothered them, and the impact of COPD on their ability to get up in the morning and on sleep. Data were compared between groups (those with and without night-time symptoms) using t-tests or Wilcoxon signed rank tests. The kappa statistic was used to assess the level of disconnect between physician and patient perceptions of the impact of night-time symptoms. RESULTS: Most patients (78%) reported night-time disturbance. Patients with night-time symptoms experienced more daytime breathlessness (mean modified Medical Research Council dyspnea scale score 2.4 versus 1.1) and exacerbations in the previous 12 months (mean 1.7 versus 0.4), and received more maintenance therapy (mean of 2.8 versus 2.3 products) than those without. Concordance between the frequency of physician-reported (67.9% of patients) and patient-reported (68.5% of patients) night-time symptoms was good. Physicians significantly underestimated the impact of COPD on the patient’s ability to get up in the morning and on sleep (fair–moderate agreement). Physician-reported night-time symptoms were present for 41.2% of patients who could be categorized by Global initiative for chronic Obstructive Lung Disease (GOLD) group (n=937), increasing from 20.9% of those in the low-risk group to 77.4% of those in the high-riskgroup. CONCLUSION: Patients with COPD experience night-time symptoms regardless of GOLD group, that impact on their ability to get up in the morning and on their sleep quality.
format Online
Article
Text
id pubmed-3849086
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-38490862013-12-13 Impact of night-time symptoms in COPD: a real-world study in five European countries Price, David Small, Mark Milligan, Gary Higgins, Victoria Gil, Esther Garcia Estruch, Jordi Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Sleep quality is often poor in patients with chronic obstructive pulmonary disease (COPD). A cross-sectional European survey investigated the prevalence of night-time symptoms in COPD to evaluate the level of disconnect between physician and patient perceptions of the presence of night-time symptoms, and to compare the characteristics of patients with and without night-time symptoms. METHODS: A total of 251 primary care physicians and 251 respiratory specialists completed record forms on 2,807 patients with COPD. The forms captured information on patient demographics, lung function, COPD severity, and symptoms. Patients completed questionnaires on the time of day when their COPD symptoms bothered them, and the impact of COPD on their ability to get up in the morning and on sleep. Data were compared between groups (those with and without night-time symptoms) using t-tests or Wilcoxon signed rank tests. The kappa statistic was used to assess the level of disconnect between physician and patient perceptions of the impact of night-time symptoms. RESULTS: Most patients (78%) reported night-time disturbance. Patients with night-time symptoms experienced more daytime breathlessness (mean modified Medical Research Council dyspnea scale score 2.4 versus 1.1) and exacerbations in the previous 12 months (mean 1.7 versus 0.4), and received more maintenance therapy (mean of 2.8 versus 2.3 products) than those without. Concordance between the frequency of physician-reported (67.9% of patients) and patient-reported (68.5% of patients) night-time symptoms was good. Physicians significantly underestimated the impact of COPD on the patient’s ability to get up in the morning and on sleep (fair–moderate agreement). Physician-reported night-time symptoms were present for 41.2% of patients who could be categorized by Global initiative for chronic Obstructive Lung Disease (GOLD) group (n=937), increasing from 20.9% of those in the low-risk group to 77.4% of those in the high-riskgroup. CONCLUSION: Patients with COPD experience night-time symptoms regardless of GOLD group, that impact on their ability to get up in the morning and on their sleep quality. Dove Medical Press 2013 2013-11-27 /pmc/articles/PMC3849086/ /pubmed/24348032 http://dx.doi.org/10.2147/COPD.S48570 Text en © 2013 Price et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Price, David
Small, Mark
Milligan, Gary
Higgins, Victoria
Gil, Esther Garcia
Estruch, Jordi
Impact of night-time symptoms in COPD: a real-world study in five European countries
title Impact of night-time symptoms in COPD: a real-world study in five European countries
title_full Impact of night-time symptoms in COPD: a real-world study in five European countries
title_fullStr Impact of night-time symptoms in COPD: a real-world study in five European countries
title_full_unstemmed Impact of night-time symptoms in COPD: a real-world study in five European countries
title_short Impact of night-time symptoms in COPD: a real-world study in five European countries
title_sort impact of night-time symptoms in copd: a real-world study in five european countries
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849086/
https://www.ncbi.nlm.nih.gov/pubmed/24348032
http://dx.doi.org/10.2147/COPD.S48570
work_keys_str_mv AT pricedavid impactofnighttimesymptomsincopdarealworldstudyinfiveeuropeancountries
AT smallmark impactofnighttimesymptomsincopdarealworldstudyinfiveeuropeancountries
AT milligangary impactofnighttimesymptomsincopdarealworldstudyinfiveeuropeancountries
AT higginsvictoria impactofnighttimesymptomsincopdarealworldstudyinfiveeuropeancountries
AT gilesthergarcia impactofnighttimesymptomsincopdarealworldstudyinfiveeuropeancountries
AT estruchjordi impactofnighttimesymptomsincopdarealworldstudyinfiveeuropeancountries